文献速递瘢痕与激光

病灶内曲安奈德与曲安奈德联合5-氟尿嘧啶治疗瘢痕疙瘩和增生性瘢痕的疗效与安全性比较:随机对照试验

Comparison of efficacy and safety of intralesional triamcinolone and combination of triamcinolone with 5-fluorouracil in the treatment of keloids and hypertrophic scars: Randomised control trial.
PubMed 文献 · Burns · 2018-10-16

该随机对照试验纳入120例瘢痕疙瘩或增生性瘢痕患者,分两组分别接受病灶内曲安奈德(TAC)单药或TAC联合5-氟尿嘧啶(5-FU)注射,每周1次共8次。108例完成研究,联合组瘢痕高度平均减少、有效率及复发率均优于单药组,结论认为5-FU+TAC安全有效且复发率更低。

要点

  • 5-FU联合TAC较单用TAC显著降低瘢痕高度(p=.000)。
  • 联合组有效率77.2%,高于单药组的49.0%(p=.002)。
  • 联合组复发率17.5%,低于单药组的39.2%(P=0.012)。

核心结论

  • 5-FU+TAC是安全、易于给药且有效的瘢痕治疗方法,随访时间较长时复发率更低。

研究设计与样本

  • 随机对照试验(RCT),在巴基斯坦拉合尔Jinnah烧伤与重建外科中心/Allama Iqbal医学院进行,时间2012年5月至2013年3月。
  • 纳入120例患者,分为A组(病灶内曲安奈德)和B组(5-FU联合曲安奈德),每周注射1次共8次。
  • 在治疗开始、第4周、第8周及治疗结束后4周评估瘢痕高度平均减少、有效性和并发症。

主要发现

  • 108例患者完成研究。
  • 有效率(初始瘢痕高度减少>50%)B组为44例(77.2%),A组为25例(49.0%)(X2=9.260,p=.002)。
  • 复发率A组为39.2%(20例),B组为17.5%(10例)(P=0.012)。
  • 平均随访22个月。

关键数值与推荐

  • 有效性定义为初始瘢痕高度减少>50%。
  • B组有效率77.2%(44例),A组49.0%(25例)(X2=9.260,p=.002)。
  • B组复发率17.5%(10例),A组39.2%(20例)(P=0.012)。

临床怎么用

  • 对于瘢痕疙瘩和增生性瘢痕,可考虑病灶内注射5-FU联合TAC,每周1次共8次。
  • 联合方案在瘢痕高度减少、有效率和复发率方面均优于单用TAC。
  • 治疗期间需在第4周、第8周及治疗结束后4周评估疗效和并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The treatment of keloid and hypertrophic scar is challenging with no universally accepted mode for permanent ablation. Conventional therapies yield unpredictable results, significant complications and require elaborate hardware. OBJECTIVE: The objective was to establish the safety and efficacy of intralesional 5-fluorouracil (5-FU) for the treatment of keloids and hypertrophic scars. STUDY DESIGN: Randomized controlled trial (RCT). PLACE AND DURATION: It was conducted at the Jinnah Burn and Reconstructive Surgery Center/Allama Iqbal Medical College, Lahore, Pakistan from May 2012 to March 2013. SUBJECTS AND METHODS: We included 120 patients divided in two groups. The group A patients received intralesional triamcinolone acetonide (TAC) and the group B patients received both 5-FU and TAC. 8 injections at a week interval were given and patients were evaluated at the start of treatment and then at 4th and at 8th week during the treatment and then 4 weeks after the end of treatment. Patents were assessed for mean reduction in scar height, efficacy and complications. RESULTS: Total of 108 patients completed the study. The mean reduction in the scar height in group B (5-FU+TAC) 1.144+.4717 was markedly better than that of group A (TAC alone) 1.894+1.0751 (t=4.781, p=.000). The efficacy (defined previously as >50% reduction in initial scar height) was superior in group B 44 (77.2%) than that of group A 25 (49.0% (X2=9.260, p=.002). Recurrence was seen in 39.2% (20) of patients of the group A while in only 17.5% (10) of the cases of group B (P=0.012). Mean follow up was of 22 months. CONCLUSION: 5-FU+TAC is safe, easy to administer and effective treatment for problematic scars and has the lower rate of recurrence on larger follow up.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Khalid FA, Mehrose MY, Saleem M, et al. Comparison of efficacy and safety of intralesional triamcinolone and combination of triamcinolone with 5-fluorouracil in the treatment of keloids and hypertrophic scars: Randomised control trial. Burns. 2018. PMID: 30340861. doi:10.1016/j.burns.2018.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。